Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Biomaterials. 2015 Feb 19;51:208–215. doi: 10.1016/j.biomaterials.2015.02.015

Figure 1.

Figure 1

(A) Schematic of NP formulations of HDACIs. (B) NP therapeutics preferentially accumulates in tumors via the EPR effect allowing for tumor tissue to receive both the radiosensitizer and radiotherapy.